PD-1

Lepu Biopharma Marches Towards First Sales as Costs Mount

Company’s Puyouheng cancer immunotherapy drug was approved for two indications in China, becoming its first commercialized product Key Takeaways: Lepu Biopharma will incur more operational costs as it builds up…

Recent Articles

RELATED ARTICLES

  1. Everest's nefecon included on national drug list
    Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  2. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  3. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  4. Cancer drug maker Genfleet joins Hong Kong IPO influx
  5. A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  6. Cancer drug maker Biostar shines on Hong Kong market debut
    2563.HK
  7. BeiGene heads for profit milestone after hemorrhaging cash
    6160.HK ONC.US 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva